10 January 2023 - - US-based Kytopen, an MIT-spin out and biotechnology company, has appointed Paul K. Wotton, Ph.D. to chair the Kytopen board of directors, the company said.

Following the appointment of Dr. Wotton, the board will comprise of five directors including Ann DeWitt, Adam Wieschhaus, Cullen Buie, and Paulo Garcia.

Dr. Paul Wotton received his Ph.D. in Pharmaceutical Sciences from the University of Nottingham and is an experienced CEO, Board Member, inventor, and serial entrepreneur.

Dr. Wotton serves on the board of directors of Vericel Corp. (NASDAQ: VCEL) and Cynata Therapeutics (ASX: CYP) and is a Founder of Avenge Bio.

Dr. Wotton was recently named as a "Top 100 Innovation CEO" by World Biz Magazine and won the Ernst & Young Entrepreneur of the Year Regional Life Sciences award in 2014.

Kytopen is an MIT startup developing platforms to accelerate the discovery, development, and manufacturing of gene-modified cell therapies.

The scalable Flowfect solution combines microfluidics and automation to make this process easier, faster, and more cost-effective than the state-of-the art solutions.

In 2017, Dr. Paulo Garcia co-founded Kytopen with Dr. Cullen Buie. Together they co-invented Kytopen's proprietary Flowfect technology for high-throughput genetic modification of cells.